A single-blind, multicenter, randomized, controlled study assessing the immunogenicity 5-months after homologous or heterologous booster vaccination in Health Care Workers primed with Ad26.COV2.S
Latest Information Update: 18 Aug 2022
At a glance
- Drugs Ad26.COV2 S (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms SWITCH
Most Recent Events
- 18 Aug 2022 New trial record
- 28 Jun 2022 Results presented at the 15th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) 2022